Hologic vs. MYGN: Which Molecular Diagnostics Player Has More Upside?

In recent times, investors have been increasingly drawn to companies operating in the molecular diagnostics space, a rapidly growing segment within the broader in-vitro diagnostics (IVD) market. According to Roots Analysis, the IVD market is projected to witness a 6.2% compound annual growth rate through 2035. Two prominent companies with a strong foothold in this space are Hologic (HOLX) and Myriad Genetics (MYGN) . Hologic’s molecular diagnostics offerings specialize in women’s health and acute respirator ...